FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310117613> ?p ?o ?g. }

• W4310117613 endingPage "9430" @default.
• W4310117613 startingPage "9429" @default.
• W4310117613 abstract "Alana von Glasenapp, MD1. Luis Villela,MD2,3,4. Henry Idrobo,MD5. Perla Colunga, MD6. Fernando Perez-Jacobo, MD7. Arianna Robles-Rodriguez, MD8. Rosa Oliday Rios, MD9. Diego Fernando Garces Paz, MD10. Denisse Castro Uriol,MD11,12. Sally Paredes, MD 11,12. Brady Beltran Garate, MD11,12. Ana Carolina Oliver Solimano, MD13. Victoria Irigoin, MD14. Alejandro Ospina-Idarraga, MD MSc15,16Humberto Martinez-Cordero, MD MSc15,16. 1Hospital Central Instituto de Prevision Social, Asuncion,Paraguay. 2Universidad Autonoma de Sinaloa Facultad de Medicina, Sinaloa,Mexico. 3Hospital Fernando Ocaranza. ISSSTE, Hermosillo, Sonora Mexico. 4Centro Medico Dr. Ignacio Chavez. ISSSTESON, Hermosillo, Sonora,Mexico. 5Prof. Universidad del Valle,Cali,Colombia. 6Servicio de Hematología, Hospital Universitario, UANL, Monterrey Nuevo León,Mexico. 7Hospital Central Norte PEMEX, Ciudad de México, Mexico. 8Hospital General de Occidente, Servicio hematología, SSA, Guadalajara, Jalisco, Mexico. 9Prof auxiliar Hospital Hermanos Ameijeira. Havanna,Cuba. 10Universidad del Cauca,Colombia. 11Hospital Edgardo Rebagliati Martins, EsSalud, Lima Peru. 12Centro de Medicina de Precisión Universidad San Martin de Porres,Lima, Perú. 13Hospital Britanico y Casmu,Montevideo,Uruguay. 14Casmu y Cosem,Montevideo,Uruguay. 15Instituto Nacional de Cancerologia, Bogota, Colombia. 16Master Program in Epidemiology-Universidad del Bosque, Bogota, Colombia. On Behalf of GELL (Grupo de estudio Latinoamericano de Linfoma)Background The standard of care (SOC) in first relapse/refractory Hodgkin Lymphoma (r/rHL) is salvage therapy, including high-dose chemotherapy (HDT) followed by autologous stem cell transplantation (ASCT). This treatment approach has been shown to improve event-free survival (EFS), progression-free survival (PFS), and freedom from treatment failure (FFTF) in controlled clinical trials. This study aims to determine the treatment patterns and outcomes of patients with Hodgkin Lymphoma in Latin America. Materials y Methods Here we present a retrospective international study of patients diagnosed with R/R HL treated at 16 centers in seven countries between 2010 and 2020. Results We found 142 patients with R/R disease fulfilling the inclusion criteria. Clinical characteristics are shown in table 1. Platinum-based regimens were the most widely used, followed by gemcitabine-based regimens and only 36 patients proceeded with ASCT (25.4%). Patients who ultimately did undergo ASCT had the best progression-free survival compared with those who did not. The median progression-free survival for the entire cohort was 17 months (95% CI 8.2-25.7). Progression-free survival for those patients who underwent ASCT was 40 months (95% CI 28-52), and for those who did not proceed to ASCT, it was only 12 months (95% CI 8-16). In the multivariate analysis, the only independent predictor of better survival was having proceeded with the transplant HR: 0.393 p= 0.030 (95% CI 0.17 -0.91). Conclusion Our retrospective study showed that access to ASCT is limited in Latin America, and the survival is lower than reported in the literature. The ASCT is essential for achieving a potential cure in R / RHL patients with the chemotherapy-sensitive disease. Health systems must guarantee access to transplantation for all patients who are candidates for this therapy. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal" @default.
• W4310117613 created "2022-11-30" @default.
• W4310117613 creator A5006395826 @default.
• W4310117613 creator A5024258786 @default.
• W4310117613 creator A5024466645 @default.
• W4310117613 creator A5031123183 @default.
• W4310117613 creator A5041674330 @default.
• W4310117613 creator A5047223130 @default.
• W4310117613 creator A5047428218 @default.
• W4310117613 creator A5050302496 @default.
• W4310117613 creator A5054752440 @default.
• W4310117613 creator A5058311223 @default.
• W4310117613 creator A5068844567 @default.
• W4310117613 creator A5068907386 @default.
• W4310117613 creator A5074270431 @default.
• W4310117613 creator A5075822029 @default.
• W4310117613 creator A5084688543 @default.
• W4310117613 date "2022-11-15" @default.
• W4310117613 modified "2023-10-03" @default.
• W4310117613 title "Treatment Patterns and Survival of Patients with Relapsed and Refractory Classical Hodgkin Lymphoma in Latin America" @default.
• W4310117613 doi "https://doi.org/10.1182/blood-2022-171102" @default.
• W4310117613 hasPublicationYear "2022" @default.
• W4310117613 type Work @default.
• W4310117613 citedByCount "0" @default.
• W4310117613 crossrefType "journal-article" @default.
• W4310117613 hasAuthorship W4310117613A5006395826 @default.
• W4310117613 hasAuthorship W4310117613A5024258786 @default.
• W4310117613 hasAuthorship W4310117613A5024466645 @default.
• W4310117613 hasAuthorship W4310117613A5031123183 @default.
• W4310117613 hasAuthorship W4310117613A5041674330 @default.
• W4310117613 hasAuthorship W4310117613A5047223130 @default.
• W4310117613 hasAuthorship W4310117613A5047428218 @default.
• W4310117613 hasAuthorship W4310117613A5050302496 @default.
• W4310117613 hasAuthorship W4310117613A5054752440 @default.
• W4310117613 hasAuthorship W4310117613A5058311223 @default.
• W4310117613 hasAuthorship W4310117613A5068844567 @default.
• W4310117613 hasAuthorship W4310117613A5068907386 @default.
• W4310117613 hasAuthorship W4310117613A5074270431 @default.
• W4310117613 hasAuthorship W4310117613A5075822029 @default.
• W4310117613 hasAuthorship W4310117613A5084688543 @default.
• W4310117613 hasConcept C144024400 @default.
• W4310117613 hasConcept C149923435 @default.
• W4310117613 hasConcept C158886217 @default.
• W4310117613 hasConcept C17744445 @default.
• W4310117613 hasConcept C199539241 @default.
• W4310117613 hasConcept C71924100 @default.
• W4310117613 hasConcept C74909509 @default.
• W4310117613 hasConceptScore W4310117613C144024400 @default.
• W4310117613 hasConceptScore W4310117613C149923435 @default.
• W4310117613 hasConceptScore W4310117613C158886217 @default.
• W4310117613 hasConceptScore W4310117613C17744445 @default.
• W4310117613 hasConceptScore W4310117613C199539241 @default.
• W4310117613 hasConceptScore W4310117613C71924100 @default.
• W4310117613 hasConceptScore W4310117613C74909509 @default.
• W4310117613 hasIssue "Supplement 1" @default.
• W4310117613 hasLocation W43101176131 @default.
• W4310117613 hasOpenAccess W4310117613 @default.
• W4310117613 hasPrimaryLocation W43101176131 @default.
• W4310117613 hasRelatedWork W1913279039 @default.
• W4310117613 hasRelatedWork W2157676827 @default.
• W4310117613 hasRelatedWork W2159514627 @default.
• W4310117613 hasRelatedWork W2201544643 @default.
• W4310117613 hasRelatedWork W2395013037 @default.
• W4310117613 hasRelatedWork W2395373766 @default.
• W4310117613 hasRelatedWork W2397242750 @default.
• W4310117613 hasRelatedWork W2781791273 @default.
• W4310117613 hasRelatedWork W2789718331 @default.
• W4310117613 hasRelatedWork W2902422580 @default.
• W4310117613 hasVolume "140" @default.
• W4310117613 isParatext "false" @default.
• W4310117613 isRetracted "false" @default.
• W4310117613 workType "article" @default.